Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Hikma Pharmaceuticals
Hikma Pharmaceuticals
Activities:
Manufacturing
Hikma focuses on a wide range of generic, branded generic and in licensed pharmaceutical products.
X
LinkedIn
Trending Articles
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
Broughton receives flexible scope ISO 17025 accreditation
New certification allows accreditation without prior approval
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Regulatory
Status update on ANDA for generic Advair Diskus (VR315 [US])
Vectura Group, an industry leading inhalation CDMO, confirms the announcement made by its partner Hikma Pharmaceuticals
Manufacturing
Hikma capitalises on Insys Therapeutics bankruptcy
The acquisition includes unit-dose nasal and sublingual spray manufacturing equipment as well as two pipeline products
Manufacturing
Hikma establishes distribution partnership with Melinta
The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region
Distribution
Hikma announces exclusive agreement with Sciecure Pharma for niche injectable antiviral medicine
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world
Regulatory
Hikma launches Dalfampridine Extended-release tablets
Hikma Pharmaceuticals, formerly known as West-Ward Pharmaceuticals, has launched Dalfampridine Extended-release tablets, 10 mg, the generic therapeutic equivalent to Ampyra
Pharmaceutical
Hikma launches Clobazam oral suspension and Clobazam tablets
Hikma Pharmaceuticals has launched Clobazam oral suspension, 2.5 mg/mL, and Clobazam tablets, 10 and 20 mg, the generic equivalent to Onfi
Recruitment
Hikma Pharmaceuticals appoints VP of Sales and Marketing
Subscribe now